---
title: "TransMedics Group, Inc. (TMDX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TMDX.US.md"
symbol: "TMDX.US"
name: "TransMedics Group, Inc."
industry: "Health Care Equipment"
datetime: "2026-05-19T20:26:42.920Z"
locales:
  - [en](https://longbridge.com/en/quote/TMDX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TMDX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TMDX.US.md)
---

# TransMedics Group, Inc. (TMDX.US)

## Company Overview

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity.

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Exchange | US Market |
| Website | [www.transmedics.com](https://www.transmedics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:14.000Z

**Overall: B (0.32)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 20 / 183 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 30.24% |  |
| Net Profit YoY | 251.23% |  |
| P/B Ratio | 4.78 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2361892657.74 |  |
| Revenue | 635890000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 45.22% | A |
| Profit Margin | 27.04% | A |
| Gross Margin | 58.16% | B |
| Revenue YoY | 30.24% | A |
| Net Profit YoY | 251.23% | A |
| Total Assets YoY | 71.32% | A |
| Net Assets YoY | 85.50% | A |
| Cash Flow Margin | 128.10% | B |
| OCF YoY | 30.24% | A |
| Turnover | 0.56 | C |
| Gearing Ratio | 65.57% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - TransMedics Group, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "30.24%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "251.23%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.78",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2361892657.74",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "635890000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "45.22%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "27.04%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "58.16%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "30.24%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "251.23%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "71.32%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "85.50%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "128.10%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "30.24%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.56",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "65.57%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 13.74 | 8/183 | 63.01 | 51.43 | 24.26 |
| PB | 4.78 | 99/183 | 13.99 | 12.58 | 9.76 |
| PS (TTM) | 3.71 | 83/183 | 8.46 | 7.67 | 6.92 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Delcath (DCTH.US) | C | A | B | A | A | A |
| 02 | Electromed (ELMD.US) | A | B | A | A | B | A |
| 03 | Intuitive Surgical (ISRG.US) | A | B | C | A | B | B |
| 04 | Stryker (SYK.US) | A | C | C | C | B | B |
| 05 | Boston Scientific (BSX.US) | A | B | C | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-13T04:00:00.000Z

Total Analysts: **12**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 50% |
| Overweight | 2 | 17% |
| Hold | 3 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 66.13 |
| Highest Target | 190.00 |
| Lowest Target | 118.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/TMDX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/TMDX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/TMDX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/TMDX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**